t-PA for Cardiac Reperfusion: Mechanism, Benefits, and Clinical Context

Reperfusion therapy aims to restore blood flow to ischemic myocardium following coronary occlusion. Three principal modalities exist: thrombolytic therapy (e.g., tissue plasminogen activator, t-PA), percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG).

t-PA: Mechanism of Action

Alteplase (recombinant t-PA) is a serine protease that binds to fibrin within thrombi, catalyzing the conversion of plasminogen to plasmin. Plasmin degrades the fibrin mesh, dissolving the clot and restoring coronary patency. Administered intravenously, its efficacy is time-dependent—greatest benefit within 3 hours of symptom onset, with diminishing returns up to 12 hours.

Clinical Benefits of Successful Reperfusion

• Preservation of myocardial contractile function
• Reduction in infarct size
• Improvement in left ventricular ejection fraction
• Decreased short- and long-term mortality
• Lower incidence of heart failure and ventricular remodeling

Clinical Decision-Making

Primary PCI is preferred when available within guideline-recommended timeframes (door-to-balloon ≤90 minutes). Thrombolysis remains crucial in non-PCI-capable centers or when PCI delays are anticipated. Contraindications to t-PA include active bleeding, recent major surgery, intracranial pathology, and severe hypertension.

The overarching goal: minimize ischemic injury, salvage viable myocardium, and improve long-term prognosis.